Leadd B.v.

Schering Aktiengesellschaft

Amgen Research (munich) Gmbh

Amgen Research Gmbh

Bertram Weiss

Jennifer Leigh Rohn

Mathieu Hubertus M Noteborn

Astrid Adriana A M Danen-van Oorschot

Peter Kufer

Tobias Raum

Patrick Hoffmann

Doris Rau

Ralf Lutterbüse

Claudia Blümel

Christoph Dahlhoff

Luisella Toschi

Jonas Anlahr

Lisa Nahrwold

Ruprecht Zierz

Bernard Jacques Haendler

Monika Lessl

Michaele Peters-Kottig

Georg Beckmann

Christoph Geserick

Anna-Lena Frisk

Ann-Lena Frisk

Ralf LUTTERBÜSE

Claudia BLÜMEL

The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CDS on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Bispecific antibody constructs for CDH3 and CD3

The present invention relates to a bispecific antibody construct comprising a first human binding domain which binds to human CDH3 on the surface of a target cell and a second binding domain which binds to human CDS on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

The invention relates to the field of apoptosis. The invention provides novel therapies, for example, novel combinatorial therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with Apoptin, especially in those cases wherein p53 is completely or partially non-functional.

Apoptin-associating protein

The invention relates to the field of apoptosis. The invention provides novel therapeutic possibilities, for example novel combinatorial therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with Apoptin, especially in those cases wherein p53 is (partly) nonfunctional.

Two human MATER proteins as well as their use for fertility disorders, therapy and diagnosis are described.

Human mater proteins

The invention relates to the human PEM polypeptide that plays an important role for the maturation of sperm and for Alzheimer's disease, and the nucleic acid that codes for them. The invention comprises the use of PEM as a target in male birth control and for the treatment and diagnosis of male infertility and Alzheimer's disease. The invention also includes a selection process for PEM antagonists as well as the production of binding molecules, which specifically detect PEM. In addition, genes that are regulated by the PEM gene are part of this invention.

Human PEM as a target for birth control and treatment of Alzheimer's disease

The invention relates to the field of apoptosis. The invention provides novel therapeautic possibilities, for example, novel combinatorial therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with Apoptin, especially in those cases wherein p53 is (partly) nonfunctional.

Growing community of inventors

Berlin, Germany

Bertram Weiss